. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 May 20;20(9):1363–1368. doi: 10.1016/j.bbmt.2014.05.014

Table 2.

¹³¹I Activity Administered, Total Absorbed Radiation Doses, and Grade 3 or 4 Regimen-Related Toxicities.

Dose to liver (Gy)^*	mCi ¹³¹I^a [MBq]	Dose to marrow (Gy)	Dose to spleen (Gy)	DLT/no. of patients treated
12	345 [12765]	12.0	15.3	0/1
22	461.0 ± 9.9 (454–468) [17057 ± 366.3 (16798–17316)]	19.2 ± 0.4 (18.9–19.5)	121.5 ± 38.8 (94.1–148.9)	0/2
24	981.3 ± 510.6 (598–1561) 39309.3 ± 18893.7 (22126–57757)]	15.3 ± 5.3 (9.3–18.9)	69.82 ± 39 (32–109.9)	0/3
26	479 ± 80.6 (422–536) [17723 ± 2982.6 (15614–19832)]	24.6 ± 26.4 (6.0–43.3)	88.6 ± 1.2 (87.8–89.5)	0/2
28	655.7 ± 277.1 (332–1029) 24259.8 ± 10250.8 (12284–38073)]	34.0 ± 13.1 (14.8–43.1)	79.5 ± 21.5 (56.4–111.2)	0/7

Mean ± SD (range).

Protocol modified to increase starting dose to 22 Gy to organ receiving highest dose after 24 Gy found to MTD in patients older than 50 treated with the same regimen.¹⁴